Palmitato de Paliperidona num Adulto com Síndrome de Asperger
DOI:
https://doi.org/10.51338/rppsm.2020.v6.i2.127Palavras-chave:
Adulto, Antipsicóticos, Síndrome de Asperger, Palmitato de Paliperidona, PirimidinasResumo
A síndrome de Asperger éuma perturbação caraterizada pelo compromisso da interação social e um padrão de comportamentos estereotipados. Estes incluem comportamentos repetitivos, irritabilidade, agressividade, hiperatividade e desatenção. O tratamento dos sintomas comportamentais constitui um desafio, com escassos estudos acerca da eficácia das diferentes abordagens terapêuticas. Este artigo é a primeira descrição do uso bem‑sucedido de palmitato de paliperidona mensal no tratamento de sintomas comportamentais num adulto com síndrome de Asperger.
Downloads
Referências
The International Statistical Classification of Diseases and Related Health Problems. Tenth Revision. Geneva: World Health Organization; 1992.
Doyle C, McDougle, C. Pharmacologic treatments for the behavioural symptoms associated with autism spectrum disorders across the lifespan. Dialogues Clin Neurosci. 2012;14:263‑79.
Lecavalier L. Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification. J Autism Dev Disord. 2006;36:1101‑14. doi: 10.1007/s10803‑006‑0147‑5.
Mirkovic B, Gérardin P. Asperger’s syndrome: What to consider?. L’Encéphale. 2019;45:169‑74. doi: 10.1016/j.encep.2018.11.005.
LeClerc S, Easley D. Pharmacological therapies for autism spectrum disorder: a review. P T. 2015;40:389‑97.
McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH. A double‑blind, placebo‑controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry. 1998;55:633‑41. doi: 10.1001/archpsyc.55.7.633.
Stigler KA, Erickson CA, Mullett JE, Posey DJ, McDougle CJ. Paliperidone for irritability in autistic disorder. J Child Adolesc Psychopharmacol. 2010;20:75‑8. doi: 10.1007/s00213‑012‑2711‑3.
Kowalski JL, Wink LK, Blankenship K, Habenicht CD, Erickson CA, Stigler KA, et al. Paliperidone palmitate in a child with autistic disorder. J Child Adolesc Psychopharmacol. 2011;21:491‑3. doi: 10.1089/cap.2011.0035.
Stigler KA, Mullett JE, Erickson CA, Posey DJ, McDougle CJ. Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology. 2012;223:237‑45. doi: 10.1007/s00213‑012‑2711‑3.
Stigler KA, Mullett JE, Erickson CA, Posey DJ, McDougle CJ. Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology. 2012;223:237‑45.
European Medicines Agency, Committee for Medicinal Products for Human Use. Summary of opinion (initial authorization) for Xeplion (paliperidone palmitate). [cited 2020 May 4]. Available from: https://www.ema.europa.eu/en/documents/smop‑initial/chmp‑summary‑positive‑opinion‑xeplion_en.pdf.
Domingues L, Cruz E. Adaptação Cultural e Contributo para a Validação da Escala
Patient Global Impression of Change. IfisiOnline. 2011;2:31‑7.
Stahl SM. Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications. 4th ed. New York: Cambridge University Press; 2013.
Rado J, Dowd SM, Janicak PG. Paliperidone ER: Reformulated antipsychotic for schizophrenia Tx. Curr Psychiatry. 2007;6:75‑82.
Leucht S, Samara M, Heres S, Patel MX, Woods SW, Davis JM. Dose equivalents for second‑generation antipsychotics: the minimum effective dose method. Schizophr Bull. 2014;40:314‑26. doi:10.1093/schbul/sbu001
McEvoy JP, Byerly M, Hamer RM, Dominik R, Swartz MS, Rosenheck RA, et al. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial [published correction appears in JAMA. 2014;312:1473]. JAMA. 2014;311:1978‑87. doi:10.1001/jama.2014.4310
